Element Materials Technology (Element) has acquired Arch Sciences Group (Arch Sciences), provider of analytical services and laboratory solutions to customers in the pharmaceuticals sector.
Arch Sciences operates two divisions: the laboratory-based analytical services division, which directly supports drug development and new product regulatory approval cycles, and the technical laboratory solutions division, which supports a wide range of third-party laboratories. The analytical services division, with laboratories in the UK and the US, provides a wide range of advanced analytical services with a global reputation for expertise in extractables and leachables testing services, and the testing of FDA-regulated consumer products.
With more than 170 employees across five locations in three countries, Arch Sciences holds a strong position in the market offering a comprehensive suite of specialist services and products that cater to customers’ testing and training requirements.
Jo Wetz, CEO of Element, said: "Our acquisition of Arch complements our existing capabilities and expertise in the Americas after a period of significant growth there, and creates a strong platform to expand the pharmaceuticals segment of our life sciences business in Europe.Following the acquisitions of Avomeen and ALG in the last 12 months, and with this new commitment to growing the life sciences business in Europe, Element is rapidly developing its position as a full-service solutions provider to the life sciences segment, which is now the most significant end market for the Element Group.”
Scott Fletcher, CEO at Arch Sciences, added: “We are looking forward to joining Element’s global family and tapping into its expertise across a wide range of services and geographies. As Element pushes forward with expansion of its life sciences offering, it’s an exciting time to enter the business, and we’re thrilled to be able to offer our expert capabilities to grow Element’s presence in Europe, the US and hopefully beyond."
